Effect of high-dose intravenous vitamin C on prognosis in patients with SARS-CoV-2 pneumonia.

BACKGROUND

Until now, the coronavirus disease 2019 (COVID-19) pandemic has affected more than 2.5 million individuals worldwide, with approximately 170,000 deaths. Currently, no treatments with robust evidence of clinical benefit exist, and utilization of experimental agents have been recommended by national and international guidelines as a part of clinical studies.

METHOD

In this retrospective study, a total of 323 patients severe acute respiratory syndrome due to PCR-documented COVID-19 infection admitted in our unit were included. Patients were categorized into two groups as those who did or did not receive high dose intravenous vitamin C. we examined the effect of high dose intravenous vitamin C administered in addition to other commonly used agents on prognosis in patients with COVID-19 pneumonia.

RESULTS

As compared to patients who did not receive vitamin C, those in the VC group were not significantly different in terms of the length of hospital stay ( = 0.05), re-admission rate ( = 0.943), admission to intensive care, need for advanced oxygen support ( = 0.488), need for advanced medical treatment ( < 0.001), and mortality ( = 0.52).

CONCLUSION

The limited evidence based on small samples precludes definitive conclusions regarding the potential efficacy of high dose vitamin C in these patients, indicating the need for further assessment within the context of clinical research.